Twinrix Hepatitis Vaccine Description
Twinrix is a bivalent vaccine containing the antigenic components used in producing HAVRIX (strain HM175) and ENGERIX-B [noninfectious hepatitis B virus surface antigen (HBsAg).].
The vaccine works by causing the body to produce its own protection (antibodies) against these diseases.
Trademarks are owned by or licensed to the GSK group of companies.
Twinrix Hepatitis Vaccine Indication
Twinrix is indicated for active immunization against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus.
TWINRIX is a vaccine used in adults, adolescents, children, and infants to prevent hepatitis A and B diseases. 100% protection cannot be guaranteed and additional doses may be required. Very common adverse events (>10% of doses) reported in adults were pain or discomfort, redness at the injection site, headache, and tiredness. Common adverse events (1% to 10% of doses) were swelling at the injection site, diarrhea, nausea and vomiting, and generally feeling unwell.
Very common adverse events (>10% of doses) reported in children were pain and redness at the injection site. Common adverse events (1% to 10% of doses) were swelling at the injection site, fever (more than 37.5°C), irritability, drowsiness, headache, loss of appetite, diarrhea, nausea, and vomiting, and generally feeling unwell. Allergic reactions may also occur.
Twinrix Hepatitis Vaccine Dosage
Twinrix is administered as an intramuscular injection. It is administered in a 3 dose series, at 0, 1, and 6 months.
Twinrix is approved for use in persons 18 years of age or older.